Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Analysts from Cantor Fitzgerald downgraded Merck’s FY2025 EPS forecast from $8.88 to $8.66 while maintaining a cautious ...

Merck's animal health division received Food and Drug Administration approval for its once-yearly injectable flea-and-tick treatment for dogs. Merck Animal Health said Thursday it expects its Bravecto ...

Merck acquired Verona Pharma for $10 billion, focusing on Verona’s first-in-class COPD drug, Ohtuvayre. Ohtuvayre’s rapid ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma's ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

New 50% copper duty, Starbucks China sale, Merck takeover move, and more ...

TopBuild has struck a deal to buy commercial-roofing services provider Progressive Roofing from alternative asset manager Bow River Capital for $810 million in cash. An internal investigation ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.